• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Immunogenicity of a Multi-Epitope Influenza Composite Peptide Vaccine Targeting Human, Swine, and Avian Viruses: Ad

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2026 Jul;20(7):e70278.
doi: 10.1111/irv.70278.
Immunogenicity of a Multi-Epitope Influenza Composite Peptide Vaccine Targeting Human, Swine, and Avian Viruses: Advancing Pandemic Preparedness

Nimisha Rikhi[SUP] 1 [/SUP], Clara J Sei[SUP] 1 [/SUP], Kellie A Fraser[SUP] 1 [/SUP], Kevin Muema[SUP] 1 [/SUP], Aba Assiaw-Dufu[SUP] 1 [/SUP], Richard F Schuman[SUP] 2 [/SUP], Gerald W Fischer[SUP] 1 [/SUP]


Affiliations
Abstract

Background: The emergence of novel reassortant influenza A virus strains and zoonotic transmission to the human population is a critical factor in the development of a global pandemic, as exemplified by the 2009 swine flu pandemic and the ongoing threat of an H5N1 avian flu pandemic. Small, unconjugated synthetic peptide vaccines comprising multiple, highly conserved epitopes may provide an important strategy towards a cost-effective, easily scalable, supra-seasonal universal influenza vaccine that can target across human, swine, and avian strains, advancing pandemic preparedness.
Objective: The aim of this study was to evaluate the immunogenicity of a synthetic, single, unconjugated, multi-epitope composite peptide vaccine targeting human, swine, and avian zoonotic viruses.
Methods: Outbred mice were immunized with different doses of the single peptide vaccine LHNVD-110, and immunogenicity was evaluated using ELISA, Hemagglutinin Inhibition Assay, Microneutralization Assay, and Enzyme-linked Lectin Assay.
Results: Strong IgG1 (Th2) and IgG2a (Th1) responses were generated against HA, NA, and Matrix epitopes, and multiple strains of influenza A/H1N1pdm09, A/H3N2, A/H5N1 (HPAI), and B/Victoria viruses. Cross-reactive, neutralizing antibodies also showed inhibition of multiple viral HA and NA subtypes, demonstrating the breadth of humoral responses.
Conclusion: This single, unconjugated, multi-epitope, composite peptide vaccine generated a robust and balanced immune response inhibiting multiple HA and NA subtypes across human, swine, and avian viruses. This approach provides a cost-effective, easily scalable, seasonal, and pandemic vaccine option with the potential of a universal influenza vaccine and efficient pandemic readiness.

Keywords: T cell epitopes; antisera neutralization; antisera titer; composite peptides; influenza; pandemic preparedness; vaccines; zoonotic viruses.

 
Back
Top